|
DE3788058T2
(de)
|
1986-08-28 |
1994-04-21 |
Teijin Ltd |
Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
|
|
MD1367C2
(ro)
|
1992-11-13 |
2000-11-30 |
Idec Pharmaceuticals Corporation |
Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
WO2001091798A2
(en)
|
2000-06-01 |
2001-12-06 |
Universite Catholique De Louvain |
Tumor activated prodrug compounds
|
|
DE60129695T2
(de)
*
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
ATE513563T1
(de)
|
2000-10-09 |
2011-07-15 |
Isis Innovation |
Therapeutische und toleranz-induzierende antikörper
|
|
US6942853B2
(en)
|
2001-01-09 |
2005-09-13 |
Queen Mary And Westfield College |
Latent fusion protein
|
|
US20040109855A1
(en)
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
US20060024272A1
(en)
|
2004-07-29 |
2006-02-02 |
Large Scale Biology Corporation |
C-terminally truncated interferon
|
|
MX2007014889A
(es)
*
|
2005-05-26 |
2008-02-19 |
Schering Corp |
Fusion de interferon-inmunoglobulina g.
|
|
JP2009529522A
(ja)
|
2006-03-10 |
2009-08-20 |
ディアト |
酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
|
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
WO2009079837A1
(en)
|
2007-12-18 |
2009-07-02 |
Hangzhou Jiuyuan Gene Engineering Co., Ltd. |
A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
JP5861223B2
(ja)
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
HRP20150664T1
(hr)
|
2010-12-03 |
2015-07-31 |
Adamed Sp. Z O.O. |
Antikancerogeni fuzijski protein
|
|
HRP20200470T1
(hr)
|
2011-01-18 |
2020-10-02 |
Bioniz, Llc |
Pripravci za modulaciju aktivnosti gama-c-citokina
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2854845B1
(en)
*
|
2012-06-01 |
2018-03-28 |
IBC Pharmaceuticals, Inc. |
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
IL270562B
(en)
*
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
GB201411506D0
(en)
*
|
2014-06-27 |
2014-08-13 |
Univ London Queen Mary |
Modified latency associated protein construct
|
|
RS59340B1
(sr)
|
2014-11-06 |
2019-10-31 |
Hoffmann La Roche |
Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
JP2019518786A
(ja)
|
2016-05-06 |
2019-07-04 |
牧林 王 |
インターロイキンの組み合せ及びその使用
|
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
|
CN111050803A
(zh)
|
2017-06-20 |
2020-04-21 |
德克萨斯大学系统董事会 |
用于治疗癌症的干扰素前药
|
|
CA3287794A1
(en)
|
2017-10-14 |
2025-10-27 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
|
CA3081539A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
CN111954680B
(zh)
|
2017-11-10 |
2024-03-15 |
新加坡科技研究局 |
IL2Rβ/共同γ链抗体
|
|
EP3727146A4
(en)
|
2017-12-19 |
2021-10-06 |
Blaze Bioscience, Inc. |
TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE
|
|
WO2020113403A1
(en)
|
2018-12-04 |
2020-06-11 |
Beijing Percans Oncology Co. Ltd. |
Cytokine fusion proteins
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
US12030721B2
(en)
|
2018-06-21 |
2024-07-09 |
Tgw Logistics Group Gmbh |
Storage and order picking system and method for picking ordered articles from a hanging bag and another load aid
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
|
CN120463822A
(zh)
|
2018-09-27 |
2025-08-12 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
JP2022502443A
(ja)
|
2018-09-28 |
2022-01-11 |
ピエール、ファーブル、メディカマン |
癌の処置のための新規な免疫サイトカイン
|
|
AU2019366956B2
(en)
|
2018-10-23 |
2025-10-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric Fc-fused proteins
|
|
MY205459A
(en)
|
2018-12-06 |
2024-10-22 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
|
|
AU2019395266A1
(en)
|
2018-12-14 |
2021-06-17 |
Proviva Therapeutics (Hong Kong) Limited |
IL-15 compositions and methods of use thereof
|
|
WO2020214690A1
(en)
|
2019-04-15 |
2020-10-22 |
Qwixel Therapeutics |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
JP2022533254A
(ja)
|
2019-05-24 |
2022-07-21 |
プロヴィヴァ セラピューティクス （ホン コン） リミテッド |
Ｉｌ－２組成物およびその使用方法
|
|
CN114127277A
(zh)
|
2019-06-05 |
2022-03-01 |
中外制药株式会社 |
蛋白酶底物和包含蛋白酶切割序列的多肽
|
|
KR20220020879A
(ko)
|
2019-06-12 |
2022-02-21 |
에스크진 파마, 아이엔씨. |
새로운 il-15 프로드럭 및 이를 사용하는 방법
|
|
CA3146156A1
(en)
|
2019-07-12 |
2021-01-21 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
MX2022000991A
(es)
|
2019-07-25 |
2022-05-24 |
Univ Chicago |
Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
|
|
EP4004026A4
(en)
|
2019-07-25 |
2023-11-15 |
Trutino Biosciences Inc. |
IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
|
|
CA3148505A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
US20220289822A1
(en)
|
2019-08-21 |
2022-09-15 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
US20220356221A1
(en)
|
2019-09-28 |
2022-11-10 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
CN115315434A
(zh)
|
2019-12-05 |
2022-11-08 |
免疫靶向有限公司 |
白细胞介素15融合蛋白和前药及其组合物和方法
|
|
MX2022007202A
(es)
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
US20240043489A1
(en)
|
2020-01-15 |
2024-02-08 |
Trutino Biosciences Inc. |
Cytokine Prodrugs Comprising a Cleavable Linker
|
|
JP7773991B2
(ja)
|
2020-03-23 |
2025-11-20 |
ザイムワークス ビーシー インコーポレイテッド |
マスクされたｉｌ１２融合タンパク質及びその使用方法
|
|
WO2021202354A1
(en)
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
AU2021248919A1
(en)
|
2020-04-01 |
2022-10-13 |
Xilio Development, Inc. |
Masked IL-12 cytokines and their cleavage products
|
|
JP7735306B2
(ja)
|
2020-04-01 |
2025-09-08 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたｉｌ－２サイトカイン及びその切断産物
|
|
IL296911A
(en)
|
2020-04-01 |
2022-12-01 |
Xilio Dev Inc |
Masked il-15 cytokines and their cleavage products
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
US11597753B2
(en)
|
2020-04-30 |
2023-03-07 |
Immune Targeting, Inc. |
Activatable IL2 composition and methods of use
|
|
JP2023526428A
(ja)
|
2020-05-19 |
2023-06-21 |
ウェアウルフ セラピューティクス， インコーポレイテッド |
活性化可能なｉｌ－１２ポリペプチド及びその使用方法
|
|
JP2024511387A
(ja)
|
2021-03-16 |
2024-03-13 |
シートムエックス セラピューティクス，インコーポレイテッド |
マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
|
EP4695281A1
(en)
*
|
2023-04-12 |
2026-02-18 |
CytomX Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|